N@N

Christopher Raymond Upgraded (BIIB) to Buy and Increased Target to $346 on, Apr 17th, 2023

Christopher Raymond of Piper Sandler, Upgraded "Biogen Inc." (BIIB) to Buy and Increased Target from $280 to $346 on, Apr 17th, 2023.

Christopher has made no other calls on BIIB in the last 4 months.

There are 8 other peers that have a rating on BIIB. Out of the 8 peers that are also analyzing BIIB, 0 agree with Christopher's Rating of Hold.

These are the ratings of the 8 analyists that currently disagree with Christopher

---

• Matthew Korn of "Morgan Stanley" Maintained at Buy with Decreased Target to $349 on, Wednesday, April 12th, 2023
• Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $325 on, Tuesday, April 11th, 2023
• Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $325 on, Thursday, March 23rd, 2023
• Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $333 on, Thursday, February 16th, 2023
• Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $340 on, Thursday, February 16th, 2023
• Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $310 on, Thursday, February 16th, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $351 on, Thursday, February 16th, 2023
• Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $315 on, Thursday, February 16th, 2023

Contributing Sources

---